Improvement in efficacy of DNA vaccine encoding HIV-1 vif by LIGHT gene adjuvant

Viral Immunology

Volumn 26, Issue 1, 2013, Pages 68-74

  Du, Jiani ^a   Wu, Xiaoyu ^b   Long, Fengying ^a   Wen, Jiejun ^a   Hao, Wenli ^a   Chen, Ran ^a   Kong, Xiaobo ^a   Qian, Min ^a   Jiang, Wenzheng ^a  

^a EAST CHINA NORMAL UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; PLASMID DNA; PROTEIN LIGHT; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VIF PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSION VECTOR; FEMALE; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HELA CELL; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; VIF GENE; VIRUS GENE; WESTERN BLOTTING;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; FEMALE; HELA CELLS; HIV ANTIBODIES; HUMANS; INJECTIONS, INTRAMUSCULAR; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED BALB C; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 14; VACCINATION; VACCINES, DNA; VACCINES, SYNTHETIC; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84874025062     PISSN: 08828245     EISSN: 15578976     Source Type: Journal    
DOI: 10.1089/vim.2012.0073     Document Type: Article

References (31)

1. Bishop KN, Verma M, Kim EY, Wolinsky SM, and Malim MH. APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog 2008;4:e1000231.
2. Bolesta E, Kowalczyk A, Wierzbicki A, Eppolito C, Kaneko Y, takiguchi M, Stamatatos L, Shrikant PA, and Kozbor D. Increased level and longevity of protective immune responses induced by DNA vaccine expressing the HIV-1 Env glycoprotein when combined with IL-21 and IL-15 gene delivery. J Immunol 2006;177:177-191.
3. Catanzaro AT, Roederer M, Koup RA, Bailer RT, Enama ME, Nason MC, Martin JE, Rucker S, Andrews CA, Gomez PL, Mascola JR, Babel GJ, Graham BS, and VRC 007 Study Team. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine 2007;25: 4085-4092.
4. Doherty TA, Soroosh P, Khorram N, Fukuyama S, Rosenthal P, Cho JY, Norris PS, Choi H, Scheu S, Pfeffer K, Zuraw BL, Ware CF, Broide DH, and Croft M. The tumor necrosis factor family member LIGHT is a target for asthmatic airway remodeling. Nat Med 2011;17:596-603.
5. Donnelly JJ, Ulmer JB, Shiver JW, and Liu MA. DNA vaccines. Annu Rev Immunol 1997;15:617-648.
6. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, and Robinson HL. DNA vaccines: A novel approach to immunization. Int J Immunopharmacol 1995;17:79-83.
7. Gamble LJ, and Matthews QL. Current progress in the development of a prophylactic vaccine for HIV-1. Drug Des Devel Ther 2010;5:9-26.
8. Gorgian Mohammady M, Bamdad T, Parsania M, Soleimanjahi H, Pouyanfard S, Hashemi H, and Asghari-Jafarabadi M. Effect of LIGHT adjuvant on kinetics of T-cell responses induced by HSV-1 DNA immunization. Iran J Immunol 2011;8:76-84.
9. Harrop JA, Reddy M, Dede K, Brigham-Burke M, Lyn S, Tan KB, Silverman C, Eichman C, DiPrinzio R, Spampanato J, Porter T, Holmes S, Young PR, and Truneh A. Antibodies to TR2 (herpesvirus entry mediator), a new member of the TNF receptor superfamily, block T cell proliferation, expression of activation markers, and production of cytokines. J Immunol 1998;161:1786-1794.
10. Henriet S, Mercenne G, Bernacchi S, Paillart JC, and Marquet R. Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors. Microbiol Mol Biol Rev 2009;73:211-232.
11. Jiang W, Jin N, Cui S, Li Z, Zhang L, Wang H, and Han W. Enhancing immune responses against HIV-1 DNA vaccine by coinoculating IL-6 expression vector. J Virol Methods 2006;136:1-7.
12. Jiang W, Ren L, and Jin N. HIV-1 DNA vaccine efficacy is enhanced by coadministration with plasmid encoding IFNalpha. J Virol Methods 2007;146:266-273.
13. Kanagavelu SK, Snarsky V, Termini JM, Gupta S, Barzee S, Wright JA, Khan WN, Kornbluth RS, and Stone GW. Soluble multi-trimeric TNF superfamily ligand adjuvants enhance immune responses to a HIV-1 Gag DNA vaccine. Vaccine 2012;30:691-702.
14. Kwon BS, Tan KB, Ni JA, Oh KO, Lee ZH, Kim KK, Kim YJ, Wang S, Gentz R, Yu GL, Harrop J, Lyn SD, Silverman C, Porter TG, Truneh A, and Young PR. A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation. J Biol Chem 1997:272:14272-14276.
15. Lecossier D, Bouchonnet F, Clavel F, and Hance AJ. Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 2003;300:1112.
16. Lee SK, Dykxhoorn DM, Kumar P, Ranjbar S, Song E, Maliszewski LE, Francois-Bongarcon V, Goldfeld A, Swamy NM, Liberman J, and Shankar P. Lentiviral delivery of short hairpin RNAs protects CD4 T cells from multiple clades and primary isolates of HIV. Blood 2005;106:818-826.
17. MacGregor RR, Boyer JD, Ugen KE, Lacy KE, Gluckman SJ, Bagarazzi ML, Chattergoon MS, Baine Y, Higgins TJ, Ciccarelli RB, Coney LR, Ginsberg RS, and Weiner DB. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: Safety and host response. J Infect Dis 1998;178:92-100.
18. Mauri DN, Ebner R, Montgomery RI, Kochel KD, Cheung TC, Yu GL, Ruben S, Murphy M, Eisenberg RJ, Cohen GH, Spear PG, and Ware CF. LIGHT, a new member of the TNF superfamily, and lymphotoxic a are ligands for herpesvirus entry mediator. Immunity 1998;8:21-30.
19. Nimal S, Heath AW, and Thomas MS. Enhancement of immune responses to an HIV gp120 DNA vaccine by fusion to TNF alpha cDNA. Vaccine 2006;24:3298-3308.
20. Piot P. The science of AIDS: A tale of two worlds. Science 1998;280:1844-1845.
21. Pissani F, Malherbe DC, Robins H, DeFilippis VR, Park B, Sellhorn G. Stamatatos L, Overbaugh J, and Haigwood NL. Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially. Vaccine 2012;30:5519-5526.
22. Qin H, Cha SC, Neelapu SS, Lou Y, Wei J, Liu YJ, and Kwak LW. Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T cell-, and not B cell-, dependent antilymphoma immunity. Blood 2009;114:4142-4149.
23. Robinson HL, and Torres CA. DNA vaccines. Semin Immunol 1997;9:271-283.
24. Sheehy AM, Gaddis NC, Choi JD, and Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002;418:646-650.
25. Simon JH, Sheehy AM, Carpenter EA, Fouchier Ra, and Malim MH. Mutational analysis of the human immunodeficiency virus type 1 Vif protein. J Virol 1999;73:2675-2681.
26. Stopak K, de Noronha C, Yonemoto W, and Greene WC. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell 2003;12:591-601.
27. Tamada K, Shimozaki K, Chapoval AI, Zhai Y, Su J, Chen SF, Hsief SL, Nagata S, Ni J, and Chen L. LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response. J Immunol 2000;164:4105-4110.
28. Tarosso LF, Sauer MM, Sanabani S, Giret MT, Tomiyama HI, Sidney J, Piaskowski SM, Diaz RS, Sabino EC, Sette A, Kalil-Filho J, Watkins DI, and Kallas EG. Unexpected diversity of cellular immune responses against Nef and Vif in HIV-1-infected patients who spontaneously control viral replication. PLoS One 2010;5:e11436.
29. Xu R, Megati S, Roopchand V, Luckay A, Masood A, Garcia-Hand D, Rosati M, Weiner DB, Felber BK, Pavlakis GN, Sidhu MK, Eldridge JH, and Egan MA. Comparative ability of various plasmid-based cytokines and chemokines to adjuvant the activity of HIV plasmid DNA vaccines. Vaccine 2008;26:4819-4829.
30. Zhai Y, Guo R, Hsu TL, Yu GL, Mi J, Kwon BS, Jiang GW, Lu J, Tan J, Ugustus M, Carter K, and Rojas L. LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer. J Clin Invest 1998;102:1142-1151.
31. Zhang Y, Jiang W, Fan Y, Wen J, Hao W, and Qian M. Engineering enhancement of the immune response to HBV DNA vaccine in mice by the use of LIGHT gene adjuvant. J Virol Methods 2008;153:142-148.